KR101900244B1 - Composition for anti-obesity comprising novel compound isolated from Ainsliaea acerifolia extract as effective component - Google Patents

Abstract

The present invention relates to a process for producing Ainsliaea The present invention relates to an anti-obesity composition comprising an ethyl acetate fraction of an acerifolia extract or a compound represented by the general formula (1), a compound represented by the general formula (2) or a mixture thereof isolated from the fraction as an active ingredient. The compounds to be displayed are excellent in the effect of inhibiting pancreatic lipase, and the compounds represented by the formula (2) of the present invention are excellent in inhibition of adipocyte differentiation and inhibiting lipid accumulation. Therefore, the compound represented by the formula (1) Compounds alone or a mixture thereof can be usefully used as a pharmaceutical composition for preventing or treating obesity and a health functional food composition for preventing or ameliorating obesity.

Description

[0001] The present invention relates to an anti-obesity composition comprising an anti-obesity composition comprising an anti-

The present invention relates to an anti-obesity composition comprising as an active ingredient a novel compound isolated from a single-puff extract.

Obesity is defined as the excess accumulation of fat in the body, and according to national health statistics, the prevalence of obesity is increasing from 26.0% in 1998 to 31.4% in 2011. Obesity has been found to be associated with complications of various adult diseases. For example, obesity patients have been reported to have a higher mortality rate compared to those who have normal weight, twice as much in the case of cirrhosis, 1.6 times in the case of cerebrovascular disease and 1.8 times in the case of coronary artery disease.

Currently, obesity treatment methods such as diet, exercise and drug therapy are being tried. Among them, the therapeutic agents for obesity, which are used as drug therapy, include appetite control, obstruction of digestion and absorption of fat, increase of energy consumption, , But there are various side effects.

Xenical (Roche) induces lipase inhibition in the pancreas and digestive system, which inhibits fat absorption, but has a low weight loss effect of 2 to 3% and often has side effects such as diarrhea and fatty liver.

In addition, Reductile (Abbott) inhibits appetite by inhibiting the reuptake of serotonin and noradrenaline, thereby reducing weight loss by 5 to 10%. However, there are side effects of cardiovascular diseases such as stroke and myocardial infarction, (EMA) and the US Food and Drug Administration (FDA) have withdrawn from the market due to prescription and discontinuation and voluntary recall recommendations. In Korea, sales were discontinued by the Food and Drug Administration in October 2010.

In addition, many of the products developed as anti-obesity drugs are prohibited from selling due to serious side effects. For example, aminophylline has been reported to have widespread adverse effects on the mental nervous system, circulatory system, and digestive system, despite its excellent body fat degradation, and penfluramine, dexfenfluramine, topiramime, or ephedrine, Sales were banned. As such, the value of natural products and medicines with anti-obesity effect is newly emerging due to the limitations of western medicine due to side effects of synthetic drugs and overcoming of chronic diseases.

Ainsliaea acerifolia is a perennial plant belonging to the family Asteraceae (Compositae), 35-80 cm high, without branches, and long brown hairs are sparse. It has been used for the treatment of rheumatoid arthritis and food poisoning.

 Korean Patent Publication No. 1405429 discloses a wild grass cosmetic containing a single-pest, Korean Patent Laid-Open Publication No. 2016-0027401 discloses a rice nucifera containing an extract of Ravine or a Pale Breeze and a preparation method thereof, Has not been disclosed for an anti-obesity composition containing a novel compound as an active ingredient.

SUMMARY OF THE INVENTION The present invention has been made in view of the above-mentioned needs, and an object of the present invention is to provide an anti-obesity composition comprising as an active ingredient a novel compound isolated from the ethyl acetate fraction of the extract of A. pneumoniae, Inhibitory effect, suppression of adipocyte differentiation and inhibition of fat accumulation, thereby completing the present invention.

In order to achieve the above object, the present invention relates to a method for producing Ainsliaea The present invention provides a pharmaceutical composition for preventing or treating obesity comprising an ethyl acetate fraction of acerifolia extract as an active ingredient.

The present invention also relates to a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof; A compound represented by the following formula 2 or a pharmaceutically acceptable salt thereof; Or a mixture thereof, as an active ingredient. The present invention also provides a pharmaceutical composition for preventing or treating obesity.

In Formula 1,

R represents coumaroyl.

In Formula 2,

R ¹ and R ² each represent a caffeoyl;

R ³ represents a methyl group.

The present invention also relates to a process for the production of Ainsliaea The present invention provides a health functional food composition for preventing or ameliorating obesity comprising an ethyl acetate fraction of an acerifolia extract as an active ingredient.

The present invention also relates to a compound represented by the formula (1) or a salt thereof; A compound represented by the formula (2) or a salt thereof; Or a mixture thereof, as an active ingredient. The present invention also provides a health functional food composition for preventing or ameliorating obesity.

The present invention relates to a process for producing Ainsliaea The present invention relates to an anti-obesity composition comprising an ethyl acetate fraction of an acerifolia extract or a compound represented by the general formula (1), a compound represented by the general formula (2) or a mixture thereof isolated from the fraction as an active ingredient. The compounds to be displayed are excellent in the effect of inhibiting pancreatic lipase, and the compounds represented by the formula (2) of the present invention are excellent in inhibition of adipocyte differentiation and inhibiting lipid accumulation. Therefore, the compound represented by the formula (1) Compounds alone or a mixture thereof can be usefully used as a pharmaceutical composition for preventing or treating obesity and a health functional food composition for preventing or ameliorating obesity.

Fig. 1 shows the results of confirming the adipocyte differentiation inhibitory effect and the fat accumulation inhibitory effect of the novel compound represented by the formula (2). A p value of less than 0.01 was considered significant.

The present invention relates to a process for producing Ainsliaea The present invention relates to a pharmaceutical composition for preventing or treating obesity, which comprises an ethyl acetate fraction of an acerifolia extract as an active ingredient.

In the present invention, it is possible to use the entire ground portion and the ground portion, and preferably, the ground portion of the ventilation odor is preferably used.

The extract of the present invention may be prepared using any conventional extraction method known in the art without limitation, and conventional extraction methods may include, but are not limited to, ultrasonic extraction, filtration and reflux extraction.

The extract of the present invention is preferably extracted with water or a lower alcohol of C ₁ -C ₄ or a mixture thereof as an extraction solvent, more preferably ethanol And more preferably 70% (v / v) ethanol. However, the present invention is not limited thereto.

In the present invention, 'fraction' means the result obtained by a fractionation method for separating a specific component or a specific group from a mixture containing various constituents. Particular fractions enriched in active material can be prepared using solvent fractions, silica gel chromatography, reverse phase chromatography, prep-HPLC, and the like.

The ethylacetate fraction of the single-puff extract may contain, as an active ingredient, a compound represented by the following formula (I), a compound represented by the following formula (II), or a mixture thereof.

[Chemical Formula 1]

In Formula 1,

R represents coumaroyl.

(2)

In Formula 2,

R ¹ and R ² each represent a caffeoyl;

R ³ represents a methyl group.

The present invention relates to a compound represented by the general formula (1) or a pharmaceutically acceptable salt thereof; A compound represented by Formula 2 or a pharmaceutically acceptable salt thereof; Or a mixture thereof, as an active ingredient. The present invention also relates to a pharmaceutical composition for preventing or treating obesity.

The compounds represented by formulas (1) and (2) of the present invention may be administered in the form of a pharmaceutically acceptable salt depending on the compound. "Pharmaceutically acceptable salts" refer to salts prepared with little or no acidity or base.

When the compounds of the present invention are relatively acidic, base addition salts can be obtained by contacting neutral forms of such compounds with a sufficient amount of the desired base and a suitable inert solvent.

Pharmaceutically acceptable base addition salts include, but are not limited to, salts of sodium, potassium, calcium, ammonium, magnesium or organic amino.

Where the compounds of the present invention are relatively basic, acid addition salts may be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid and a suitable inert solvent.

Pharmaceutically acceptable acid addition salts include those derived from propionic acid, isobutyric acid, oxalic acid, malic acid, malonic acid, benzoic acid, succinic acid, sueric, fumaric acid, mandelic acid, phthalic acid, benzenesulfonic acid, Monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydrogen iodide or phosphorous acid, and the like. ≪ / RTI > but are not limited to, the salts formed with

It also includes, but is not limited to, salts of amino acids such as arginate and analogs of organic acids such as glucuronic or galactunoric acids.

The compounds of the present invention may exist in unsolvated as well as solvated forms, including hydrated forms depending on the compound. The compounds of the present invention may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.

In addition, the compounds of the present invention may have an asymmetric carbon atom or a double bond, which is an optical center depending on the compound, and thus there may exist racemates, enanthiomers, diastereomers, geometric isomers and the like, .

The pharmaceutical composition of the present invention may be various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used.

Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories.

Examples of non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of suppositories include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and it is preferable to select the intravenous, intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine or intracerebral injection methods during parenteral administration, But is not limited to.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

The dosage of the composition of the present invention may be varied depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease.

The present invention relates to a process for producing Ainsliaea The present invention relates to a health functional food composition for preventing or ameliorating obesity comprising an ethyl acetate fraction of an acerifolia extract as an active ingredient.

In the present invention, it is possible to use the entire ground portion and the ground portion, and preferably, the ground portion of the ventilation odor is preferably used.

The extract of the present invention may be prepared using any conventional extraction method known in the art without limitation, and conventional extraction methods may include, but are not limited to, ultrasonic extraction, filtration and reflux extraction.

The extract of the present invention is preferably extracted with water or a lower alcohol of C ₁ -C ₄ or a mixture thereof as an extraction solvent, more preferably ethanol And more preferably 70% (v / v) ethanol. However, the present invention is not limited thereto.

In the present invention, 'fraction' means the result obtained by a fractionation method for separating a specific component or a specific group from a mixture containing various constituents. Specific fractions enriched in active material can be prepared using techniques such as solvent fractions, silica gel chromatography, reverse phase chromatography, prep-HPLC, and the like.

The ethylacetate fraction of the single-puff extract may contain, as an active ingredient, a compound represented by the following formula (I), a compound represented by the following formula (II), or a mixture thereof.

[Chemical Formula 1]

In Formula 1,

R represents coumaroyl.

(2)

In Formula 2,

R ¹ and R ² each represent a caffeoyl;

R ³ represents a methyl group.

The present invention relates to a compound represented by the general formula (1) or a salt thereof; A compound represented by the formula (2) or a salt thereof; Or a mixture thereof, as an active ingredient. The present invention also relates to a health functional food composition for preventing or ameliorating obesity.

The health functional food composition of the present invention can be prepared by any one selected from beverage, ring, tablet, capsule and acid, or by adding it to other food or ingredients of food, Can be suitably manufactured.

Examples of foods to which the health functional food composition of the present invention can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, Beverage, tea, drink, alcoholic beverage, and vitamin complex, and includes all the health foods in the ordinary sense.

The health functional foods include various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alkynic acid and its salts, , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination.

The health functional food composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.

Example  One. A single blow  Isolation of a single compound from the extract

1-1. Preparation of organic solvent fractions from sweet algae extract

Fresh breeze ( Ainsliaea acerifolia ) were pulverized to an appropriate size, and then extracted three times with 70% ethanol at room temperature, followed by concentration under reduced pressure to obtain a 70% ethanol extract (203.3 g). The 70% ethanol extract was suspended in 4 L of 10% methanol, and n-hexane was fractionated twice in 4 L portions to obtain n-hexane fractions. Subsequently, the water fraction was fractionated twice with 4 L each of ethyl acetate and butanol sequentially, and the remainder was used as a water fraction. There were obtained 73.8 g of the n-hexane fraction, 56.0 g of the ethyl acetate fraction, 28.0 g of the butanol fraction and 186.0 g of the water fraction.

1-2. Isolation of active ingredient from organic solvent fractions

It was confirmed that the ethyl acetate fraction obtained from the above-mentioned 1-1 showed the pancreatic lipase inhibitory activity. To isolate the active ingredient from the ethyl acetate fraction of the above-mentioned odor pest, HW-40 reverse phase column chromatography (Toyopearl HW-40 column , 20%, 40%, 60%, and 100% methanol (v / v) using the developed solvent, H2O, coarse grade, 2.8 cm × 51 cm. The fractions were divided into five fractions according to the above sorting order, and the respective fractions were concentrated and dried.

The third fraction of the five fractions was subjected to column chromatography (YMC GEL ODS AQ 120-50S column, 1.1 cm x 40 cm, elution solvent: 20% methanol (v / v) YMC Co., Kyoto, Japan) and then purified by HPLC (20% acetonitrile, YMC-Pack ODS A-302 column, 4.6 mm x 150 mm, YMC Co., Kyoto, Japan) The compound and the compound represented by the formula (2) were respectively separated.

1-3. Structural analysis of the compound represented by formula (1)

[Α] D value, UV spectrum, IR spectrum, HR-FAB-MS spectrum, ¹ H-NMR and ¹³ C-NMR of the compound of the formula (1) The compound of formula (1) was identified.

[[alpha]] _D : +23.0 [deg.] (c 0.1, MeOH);

UV max (MeOH) nm: 207.0, 246.0, 301.0;

IR (nujol) cm ^{- 1} : 3400, 1746, 1705, 1512, 1435, 1255, 1151;

HR-FAB-MS: 577.2093 [ M + Na] + (C 30 H 34 O 10 Na);

NMR (DMSO-d6): < EMI ID =

NMR data ( ¹ H NMR: 600 M Hz, ¹³ C NMR: 150 M Hz) of the compound represented by the formula ( ¹ ) 隆_H (J in Hz) δ _C , mult. One 2.99 (dd, 16.8, 8.4) 46.2 2α 2.33 (m) 38.6 2β 1.96 (m) 3 4.63 (m) 81.3 4 - 150.8 5 2.78 (dd, 9.6, 9.6) 51.8 6 4.26 (dd, 9.6, 9.3) 85.2 7 2.89 (m) 46.4 8α 2.26 (m) 31.6 8β 1.45 (m) 9α 2.18 (m) 34.4 9β 2.50 (m) 10 - 150.0 11 - 142.1 12 - 172.3 13a 6.09 (d, 3.0) 120.4 13b 5.56 (d, 3.0) 14a 5.01 (s) 114.7 14b 4.91 (s) 15a 5.43 (br s) 113.6 15b 5.35 (br s) One' 4.45 (d, 7.2) 103.1 2' 3.87 (m) 78.2 3 ' 3.37 (t, 8.4) 75.3 4' 3.28 (m) 71.8 5 ' 3.26 (m) 77.9 6'a 3.86 (dd, 12.0, 2.4) 62.8 6'b 3.68 (dd, 12.0, 5.4) One" - 130.9 2" 7.56 (d, 7.8) 129.0 3 " 7.37 (d, 7.8) 130.0 4" - 150.1 5 " 7.37 (d, 7.8) 130.0 6 " 7.56 (d, 7.8) 129.0 7 " 7.58 (d, 15.6) 144.6 8" 6.48 (d, 15.6) 121.7 9 " - 172.3

1-4. Structural analysis of the compound represented by formula (2)

[Α] D value, UV spectrum, IR spectrum, HR-FAB-MS spectrum, ¹ H-NMR and ¹³ C-NMR of the compound represented by the general formula (2) As described above, compound 2 was identified as methyl 3,5-di-O-caffeoyl-epi-quinate.

[[alpha]] _D : -120.0 [deg.] (c 0.2, MeOH);

UV max (MeOH) nm: 296, 330;

IR (nujol) cm ^{< -1} > ^{: 1} 3410, 1685, 1605, 1520, 1160, 976, 810;

HR-FAB-MS: 531.1506 [M + H] < ⁺ > (C ₂₆ H ₂₇ O ₁₂ );

_{^{1 H NMR (CD 3 OD,}} 600 MHz): δ 7.61, 7.54 (each 1H, d, J = 15.6 Hz, H-7 ', H-7 "), 7.07 (1H, d, J = 2.0 Hz, H (1H, dd, J = 8.4 Hz), 7.06 (1H, d, J = 2.0 Hz, H- , 2.0 Hz, H-6 "), 6.78 (1H, d, J = 8.4 Hz, H-5 '), 6.77 (1H, d, J = 8.4 Hz, H- (d, J = 15.6 Hz, H-8 ', H-8''), 5.43 (1H, m, H-3) , 3.0 Hz, H-4) , 3.69 (3H, s, OCH3-7), 2.31 (1H, dd, J = 14.4, 3.6 Hz, H-6 ax), 2.23 (1H, dd, J = 13.6, 3.0 Hz, H-2 _eq ), 2.11 (1H, dd, J = 13.6, 9.0 Hz, H-2 _ax ), 2.06 (1H, m, H-6 _eq );

_{^{13 C NMR (CD 3 OD,}} 150 MHz): δ 180.1 (C-7), 168.0 (C-9 ', C-9 "), 148.1 (C-4"), 147.9 (C-4'), 145.5 (C-3 ''), 145.4 (C-3 '), 145.3 (C-7', C-7 ''), 126.7 , C-6 "), 111.5 (C-5 ', C-5"), 114.7 (C-1), 73.1 (C-5), 71.8 (C-4), 71.1 (C-3), 52.9 (C-7 MeO), 39.5 (C-2), 36.3 (C-6).

2. Pancreatic lipase inhibitory effect

Measurement of pancreatic lipase inhibitory activity was measured using porcine pancreatic lipase.

(10 units) of porcine pancreatic lipase (Sigma, St. Louis, Mo., USA) and 169 μL of a mixture of 10 μM (10 mM MOPS (morpholinepropanesulphonic acid) and 1 mM EDTA, pH 6.8) Tris buffer solution (100 mM TrisHCl and 5 mM CaCl2, pH 7.0) is prepared by mixing. 20 μL of the compound represented by Chemical Formula 1 and the compound represented by Chemical Formula 2 prepared as various concentrations and the positive control drug Orlistat (Roche, Basel, Switzerland) were mixed and incubated at 37 ° C. for 15 minutes. Then, 5 μL of a substrate solution [10 mM p-NPB (p-nitrophenylbutyrate) in dimethylformamide] is added, followed by further incubation for 15 minutes. Pancreatic lipase activity was measured by absorbance of p-nitrophenol (p-nitrophenol) obtained by hydrolysis of p-NPB by pancreatic lipase using an ELISA instrument (BIO-TEK, Synergy HT, USA) at a wavelength of 405 nm.

The degree of inhibition of pancreatic lipase activity was calculated by converting the ratio of the absorbance suppressed by the compound represented by the formula (1) and the compound represented by the formula (2) to the percentage value, and the concentration (IC ₅₀ ) for inhibiting the activity of the pancreatic lipase by 50% Respectively.

Measurement results of inhibitory activity of pancreatic lipase sample IC ₅₀ ([mu] M) The compound represented by the formula (1) 36.5 ± 1.5 The compound represented by the formula (2) 127.1 ± 1.5 orlistat 0.6 ± 0.2

It was confirmed that both the compound represented by formula (1) and the compound represented by formula (2) were effective in inhibiting the activity of pancreatic lipase. Therefore, the compound represented by the formula (1) and the compound represented by the formula (2) according to the present invention are thought to have an anti-obesity effect and a body fat reducing effect.

Example  3. 3T3-L1 Fat precursor cells  Used Anti-obesity  effect

3-1. Preparation of 3T3-L1 adipose precursor cells

3T3-L1 adipose precursor cells were purchased from the American Cell Line Bank (ATCC) and used for the experiments. 3T3-L1 is a widely used cell line for studying the metabolic process of adipocytes. As the differentiation of these cells becomes more active, the accumulation of adipocytes in the adipocytes becomes active and induces obesity. Therefore, when a cell suspected of having an anti-obesity effect is treated with the cell, the smaller the cell differentiation, the greater the anti-obesity effect.

3-2. Differentiation of 3T3-L1 adipocytes into adipocytes

3T3-L1 mouse precursor adipocytes were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) at 37 ° C and 5% CO ₂ . 3T3-L1 precursor adipocytes were dispensed into 24-well plates at 5 x 10 ⁴ cells per well, and then maintained for two more days after the well was 100% filled with precursor adipocytes. The precursor adipocytes were induced for 2 days with 10% FBS DMEM medium containing MDI (0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 1 μM dexamethasone, 1 μM insulin) and cultured for 2 days with 10% FBS DMEM containing [mu] M insulin. Subsequently, the cells were replaced with 10% FBS DMEM medium for 2 days every 4 days. During the induction of adipocyte differentiation, the compounds of formula (2) according to the present invention were treated at 25 μM, 50 μM and 100 μM concentration, and the degree of adipocyte differentiation was observed on the 8th day when the differentiation was completed.

3-3. Oil red O dyeing and analysis

Oil red O was stained to confirm the accumulation of fat. The degree of differentiation of adipocyte derived from the above experiment was firstly confirmed by microscopic examination through oil red O staining and the degree of differentiation of cells in the degree of adipocyte staining was measured at 500 nm absorbance.

As a result, as shown in FIG. 1, the compound of Formula 2 according to the present invention inhibited the differentiation of 3T3-L1 adipocyte precursor cells in a concentration-dependent manner, and consequently decreased the amount of fat (FIG. 1) .

Therefore, the compound of formula (2) according to the present invention is expected to have anti-obesity effect and body fat reduction effect.

Claims (8)

delete delete delete A pharmaceutical composition for preventing or treating obesity, which comprises a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Chemical Formula 1]

In Formula 1,
R represents coumaroyl. The pharmaceutical composition for preventing or treating obesity according to claim 4, wherein the compound represented by the formula (1) is isolated from the ethyl acetate fraction of Ainsliaea acerifolia extract. The method of claim 5, wherein the extraction solvent of the extract is danpungchwi water, C ₁ ~ C ₄ lower alcohol or prevention of obesity or pharmaceutical composition, characterized in that a mixture thereof. delete A health functional food composition for preventing or ameliorating obesity, which comprises a compound represented by the following formula (1) or a salt thereof as an active ingredient:
[Chemical Formula 1]

In Formula 1,
R represents coumaroyl.

Images